Now Available!
"Coronary
Artery Revascularization: Developments and Trends in Restenosis Prevention
and Treatment - Beyond Drug-Eluting Stents"-
MedIntelliBase™ MarketTrack
- MIB #001-05
Databases Just Updated!
-- Updates due December 1, 2006 -- including Emerging Technologies & Late Breaking Trials from TCT-06 & the AHA meetings!
Detailed Market Projections!
-- released November 2006!
Detailed Reimbursement Coding Maps!
-- released June 2006!
Now you can have at your fingertips in-depth reporting, analysis and projections. Coronary
Artery Revascularization reports on the drugs, biological
agents, medical devices and systems commercial or in development to treat
or prevent restenosis and achieve successful revascularization.
This multi-dimensional, comprehensive
tool enables users to quickly navigate this vast market in real-time by
searching for products, companies, and clinical trial information on its
three (3) electronically cross-referenced MIB SMArt Databases™:
- Emerging & Established Technologies - SMArt Chart
- Pivotal Clinical Trials and Registries - SMArt Trials
- Competing Companies - SMArt Companies
This MedIntelliBase™ MarketTrack also contains in-depth and up-to-date MIB Analysis including:
- SMArt Stats - detailed, downloadable and customizable market stats and projections
- SMArt Codes - detailed, downloadable and customizable reimbursement coding maps
- SMArt Volumes™ e-Report, a unique 300-page market
report discussing the market, commercial, biological, physiological and
clinical issues as well as the rapidly changing and expanding array
of interventional modalities now available or being developed to achieve
successful coronary revascularization.
Coronary
Artery Revascularization: Developments and Trends in Restenosis Prevention
and Treatment - Beyond Drug-Eluting Stents addresses
each major modality currently used in coronary interventions, and offers
a unique historical perspective going back to the beginning of interventional
medicine. This MedIntelliBase MarketTrack also examines present and future products, providing information
about the specific developments underway by all competitors, large and
small, for each modality. Combined the databases and e-report are the equivalent of an 800+ page market report!
- nearly 300 companies & institutions
- over 170 technologies
- approaching 620 products
- exceeding 325 pivotal
clinical trials and registries
- nearly 1700 published sources...and growing
|
|
Technologies Covered (partial listing):
|
|
Atherectomy
Gene Therapy
Bare Metal Stents
Drug-Eluting Stents
Local Drug Delivery
Bioabsorbable Stents
Systemic Pharmaceuticals
|
Therapeutic Ultrasound
Photodynamic Therapy
Hydrogel Polymers
Brachytherapy
Nitric Oxide
Paclitaxel
VEGF
|
|
Companies covered (partial listing):
|
| Guidant
Angiotech
Cordis / J&J
Boston Scientific
Abbott Laboratories
Bristol-Myers Squibb
Miravant Medical Tech.
Biocompatibles International
|
Orbus Medical Technologies
Angiogene Pharmaceuticals
Biosensors International
Medtronic Vascular
Conor Medsystems
Vascular Concepts
NitroMed
Biotronik
|
This exclusive web-based tool
is filled with invaluable information and will be continually updated
as industry developments occur.
This MedIntelliBase MarketTrack is now available on-line with
the purchase of a yearly subscription, via The Next Phase's secure website.
Yes - I'd like to see a detailed Table of Contents (in PDF) & I'll Contact the MIB Team for detailed Indices of 3 Databases' Contents
Yes - I'd like to see sample MarketTrack
pages and database search results:
Or
Yes - I'd like to know more about...
New Subscription Pricing based on my organization's needs!
Order Information on the FULL CV MarketTrack Available Now!
Or
Last updated November 20, 2006.
ABOUT US |
PUBLISHED PRODUCTS | MEDINTELLIBASE
LOGIN |
MEDINTELLIGUIDE LOGIN |
Search |
Contact |
Privacy |
Home
The Next Phase Publishing, Inc.
Phone: 425.869.8724 / Fax: 425.869.9397
, to speak with us about our products.
, with questions or comments about this
web site.
Copyright © 2007
The Next Phase Publishing, Inc. All rights reserved.
|
